What Broncho-Vaxom treats: Main Uses and Benefits

The therapeutic use of this medicine focuses on prevention and support in chronic respiratory situations, targeting conditions characterized by periods of heightened symptoms and episodic manifestations. This approach is generally used to provide preventative support against the pattern of frequent, recurring respiratory tract infections (RTIs) in both adults and children.

Therapeutic Domains and Benefits

The core therapeutic domain may contribute to reducing the frequency of illness episodes, which assists in easing the overall symptom burden associated with successive colds, coughs, and fever over a given period. It is commonly used in conditions presenting with acute episodes and recurrent manifestations, such as chronic bronchitis and recurrent upper and lower respiratory tract infections.

It is applied in addressing symptom clusters related to recurrent infectious flare-ups or acute exacerbations in chronic lung conditions. When infections do occur, the medicine may help patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load, providing supportive relief when symptoms interfere with routine activities.

---

Quick Fact: Support for Recurrent Symptom Burden

Property	Benefit
Primary Goal	May contribute to reducing the frequency of illness episodes
Symptom Focus	Easing the overall symptomatic burden of recurrent respiratory illness
Clinical Context	Applied in contexts involving acute or disruptive symptom patterns in chronic lung conditions

Who can and cannot use Broncho-Vaxom?

This section outlines the official eligibility and non-eligibility criteria for Broncho-Vaxom, based strictly on governmental regulatory documents.

---

Official Eligibility Status

Population Category	Eligibility Status (Regulatory Basis)
Allowed Populations	Adults and children over 6 months of age.
Contraindicated Populations	Individuals with known hypersensitivity to the active substance (lyophilized bacterial lysates OM-85) or to any of the excipients.
Use Not Recommended	Children under 6 months of age (due to limited clinical data).
	Patients with hepatic or renal disorders (due to lack of efficacy/safety data).
	For the prevention of pneumonia (due to lack of efficacy data).

---

Special Considerations

Physiological State	Status/Restriction
Pregnancy	Avoidance is preferable as a precautionary measure due to limited available clinical data.
Lactation (Breast-feeding)	Caution is advised; no specific studies have been conducted.

The regulatory profile defines who can take this medicine primarily through a strict contraindication for hypersensitivity and an age restriction, recommending against use in infants younger than six months. Use is also not recommended for certain patient populations, such as those with hepatic or renal impairment, due to a lack of supporting clinical data on safety and efficacy in these groups.

The regulatory profile for Broncho-Vaxom (Polybacterial Lysate OM-85) in the section on interactions with other medicines and products is currently defined by the absence of specific documented interactions from government authorities.

Interaction Scope

Category	Regulatory Status
Interacting Medicines/Substances	None documented
Mechanistic Basis of Interactions	None documented
Timing-based Separation Rules	None documented
Interaction-related Restrictions	None documented
Population-specific Notes	None documented

Interaction Classifications and Constraints

Official regulatory documents consistently state that no specific drug-drug interactions for Polybacterial Lysate OM-85 are currently known. This finding applies across all high-level interaction classifications. Since no interactions are documented, there are no formal prohibitions or contraindicated combinations listed based on interaction risk. No warnings regarding the co-administration of the medicine with food, alcohol, or herbal products are specified in the official interaction section of the labeling.

Official Interaction Statements

• The official prescribing information from regulatory authorities confirms that no specific drug-drug interactions are currently known to date.
• Formal studies to assess potential pharmacokinetic interactions (such as those mediated by hepatic enzymes or transporters) have not been detailed in the official regulatory documentation.
• No mandatory separation rules or timing requirements for co-administration with other medications are prescribed in the official product information.

This complete absence of documented interactions dictates the official regulatory structure of this product’s interaction profile, confirming that no external medicinal products or substances are formally identified as interacting agents.

How Broncho-Vaxom Works

The biological action of the bacterial components is achieved through the Gut-Lung Immune Axis, where the components are absorbed in the intestine and act as an Immunological Agonist on Pattern Recognition Receptors (PRRs), primarily within the Peyer's patches. This interaction initiates the maturation of antigen-presenting cells (APCs) and activates the common mucosal immune system.

The activated immune cells then migrate to the respiratory mucosa, driving the proliferation and differentiation of T- and B-lymphocytes. This results in the formation of long-term immunological memory and significantly increases the localized production of secretory Immunoglobulin A (sIgA) and Immunoglobulin G (IgG). This humoral and cellular activation results in increased local immunological specificity and readiness against the target bacterial components.

The mechanism also involves the modulation of the cytokine profile and an enhancement of phagocytic activity by respiratory macrophages. These combined actions modulate the localized immune response, altering the kinetics of pathogen clearance and influencing the subsequent physiological characteristics of the mucosal barrier response.

Broncho-Vaxom is administered exclusively via the oral route, with its usage defined by a specific intermittent cyclic regimen for prophylaxis against recurrent respiratory tract infections. The standard administration pattern involves taking the medicine once daily for 10 consecutive days each month.

Dosage and Administration Protocol

The medicine is available in two standardized strengths for distinct populations. Adults and adolescents over 12 years of age are typically prescribed the 7 mg hard capsule dose. For pediatric use, children from six months up to 12 years of age utilize the 3.5 mg dose, which is supplied either as a hard capsule or as granules in a sachet. Use in infants under six months is not recommended.

To ensure proper absorption, the medicine is taken on an empty stomach. The 3.5 mg pediatric capsule is designed with flexibility: if the capsule cannot be swallowed whole, the contents may be poured out and mixed into a suitable quantity of water, milk, or fruit juice. This mixture is then consumed immediately and in its entirety.

Treatment Schedule and Duration

The overall course for prophylactic treatment consists of three consecutive monthly cycles. In each of the three months, the regimen involves a 10-day dosing schedule, followed by a period of cessation. This cycle can be repeated if necessary. If a dose is missed, the guidance states it is not compensated for by taking a double dose; the treatment schedule simply continues with the next planned daily dose. Treatment may be initiated even during the acute phase of a respiratory infection, provided it is administered alongside appropriate initial therapeutic measures.

Recent Clinical Evidence Overview

Broncho-Vaxom (OM-85) is an oral bacterial lysate investigated for its role as an immunomodulator in the prevention of recurrent respiratory tract infections (RRTIs).

Clinical research primarily focuses on two main populations: children susceptible to RRTIs and adults with chronic obstructive pulmonary disease (COPD) or chronic bronchitis.

---

Pediatric Recurrent Respiratory Tract Infections (RRTIs)

Meta-analyses in children suggest an association between the use of OM-85 and a reduced frequency of RRTIs, as well as a decrease in the total duration of these infections. Studies have also observed a lower requirement for antibiotics in children receiving the product compared to placebo groups. The data suggest that this effect may be more pronounced in children identified as being at high risk for RRTIs.

---

Chronic Obstructive Pulmonary Disease (COPD) and Bronchitis

For adults with COPD or chronic bronchitis, systematic reviews have explored the use of OM-85 to reduce the rate of acute exacerbations (AECs). While some studies indicated that a greater proportion of patients receiving OM-85 remained free from AECs compared to placebo, the overall data regarding the reduction in the cumulative number of exacerbation episodes per patient have been mixed, with some analyses showing no significant difference. These findings highlight a need for further large-scale, high-quality randomized controlled trials to clarify its exact role in this population.

---

Immune System Modulation

Research programs have included studies focused on the product's influence on the immune system, including the activation of macrophages and the modulation of cytokine levels, which are components of the body's defense response.

Common questions about Broncho-Vaxom (FAQ)

---

Q: Can Broncho-Vaxom help prevent recurrent ear infections or sinusitis?

Broncho-Vaxom is officially indicated for the prevention of recurrent respiratory tract infections (RRTIs). Recurrent ear infections (otitis media) and sinusitis are generally considered types of RRTIs. However, the official product labeling does not specifically list these conditions individually as separate indications.

---

Q: Is it normal to feel worse or have mild flu-like symptoms at the beginning of the treatment cycle?

Regulatory documents list systemic reactions like fever (pyrexia) and fatigue (asthenia) as uncommon side effects. If a patient experiences severe or persistent symptoms, such as fever or respiratory symptoms, the official prescribing information states that treatment should be discontinued if observed.

---

Q: Can Broncho-Vaxom be taken at the same time as antibiotics when treating an acute infection?

According to official information, treatment can be started during the acute phase of an infection, provided it is administered alongside appropriate initial therapeutic measures, which commonly includes antibiotics. No specific drug-drug interactions are currently known.

---

Q: Does Broncho-Vaxom interact with common over-the-counter pain relievers or fever reducers?

Official regulatory documents consistently state that no specific drug-drug interactions are currently known for this medicine. This means no formal warnings or constraints regarding its use with common over-the-counter pain relievers or fever reducers are specified in the product labeling.

---

Q: Do you need to stop taking Broncho-Vaxom if you develop a respiratory infection during the 10-day cycle?

Official product information advises that the treatment may be initiated even during the acute phase of an infection. Treatment should be discontinued immediately if signs of allergic reactions, or severe or persistent respiratory or gastrointestinal symptoms, are observed.

---

Q: Can I take other immune-boosting supplements like Vitamin C or Zinc while on Broncho-Vaxom?

The official labeling does not specify warnings regarding the co-administration of the medicine with herbal products or food in the interaction section. No specific drug interactions with supplements are known.

---

Q: Does Broncho-Vaxom have any known interaction with allergy medications or antihistamines?

Official prescribing information confirms that no specific drug-drug interactions are currently known for the active ingredient, Polybacterial Lysate OM-85. No formal warnings or constraints regarding its use with allergy medicines or antihistamines are listed in the official documents.

---

Q: Why is it recommended to take Broncho-Vaxom on an empty stomach?

Official guidance recommends taking the medicine on an empty stomach. This instruction is given specifically to help ensure the proper absorption of the active bacterial lysate components (OM-85) from the intestine into the bloodstream.

---

Q: Can Broncho-Vaxom be used by people with autoimmune diseases?

The official labeling does not list autoimmune diseases as a contraindication. However, it also does not provide specific data or guidance regarding use in this patient population. Use is generally not recommended for those with hepatic or renal impairment due to a lack of clinical data.

---

Q: Can a doctor prescribe Broncho-Vaxom for an older person with a weaker immune system?

The medicine is indicated for use in adults and children over six months of age. There are no specific age-related restrictions, special dosage considerations, or warnings documented for the elderly population in the official labeling.

---

Q: Does Broncho-Vaxom impact the effectiveness of oral contraceptives?

Official regulatory documents state that no specific drug-drug interactions are currently known for this medicine. This means no formal warnings or constraints regarding the co-administration of this medicine with oral contraceptives are listed in the product information.

---

Q: Can Broncho-Vaxom help reduce the need for antibiotics over time?

Clinical evidence summarized in official documents indicates that in studies involving children, there was an association between using the medicine and a lower requirement for antibiotics compared to placebo groups.

---

Q: Is it safe to take Broncho-Vaxom if I have a history of severe allergies?

The medicine is contraindicated (should not be used) in individuals with a known hypersensitivity to the active substance, Polybacterial Lyophilisate OM-85, or to any of the inactive ingredients. Treatment should be stopped immediately if any signs of an allergic reaction are observed.

---

Q: Are frequent headaches a common concern during the 10-day cycle?

Headache is listed as a Common side effect in the official safety profile. This indicates it is one of the more frequently reported adverse reactions, affecting between 1 in 100 and 1 in 10 users.

---

Q: Does Broncho-Vaxom require refrigeration or special storage?

The official storage conditions mandate that the product must be stored at a temperature not exceeding 30 C and kept in the original package away from moisture. It does not require refrigeration.

Storage and Disposal Requirements for Broncho-Vaxom

The official labeling mandates specific environmental conditions to protect the integrity of the Polybacterial Lysate active ingredient.

Storage Conditions

Requirement	Official Rule
Temperature Limit	Store at a temperature not exceeding 30 C
Packaging	Must be kept in the original package to protect from moisture
Shelf Life	Has a labeled shelf life of 5 years; do not use after the expiry date
Child Safety	Must be kept out of the sight and reach of children

Disposal Instructions

Unused or expired Broncho-Vaxom should be managed through drug take-back programs whenever possible. If such a program is not available, the product should be mixed with an undesirable substance, sealed in a container, and placed in the household trash. This procedure prevents the medicine from entering wastewater and deters accidental ingestion. Remove or scratch out all identifying information on the packaging before discarding.